Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.

View in: PubMed

subject areas

Double-Blind Method
Fibroblast Growth Factors
Humans
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Treatment Outcome

authors with profiles

Mary Rinella